Tacrolimus challenger with cleaner safety profile heads into Phase 3, but runway expires before trial reads out

Updated 33d ago

Eledon is a clinical-stage company developing a targeted immunosuppressant for kidney transplant rejection that is not yet approved.

Tegoprubart, a CD40-CD154 costimulation blocker for kidney transplant rejection, posted superior kidney function versus tacrolimus at 18 months but missed its Phase 2 primary endpoint, leaving approvability contingent on Phase 3 non-inferiority results the company cannot fund past Q2 2027. The thesis resolves on whether Phase 3 data, requiring a raise well before readout, confirms the functional and safety advantages seen in BESTOW long-term follow-up. A $89M cash position covering only to Q2 2027 against a 600-patient global trial is the central structural risk.

Status

Challenged

Conviction

Current Thesis Drivers

18-month BESTOW eGFR ~74 vs ~61 mL/min, p≤0.05, statistically significant
FDA End-of-Phase 2 meeting completed; Phase 3 framework established
Phase 2 primary endpoint (eGFR) missed statistical significance
Runway to Q2 2027 does not cover Phase 3 readout

What could change the thesis?

Phase 3 initiation late 2026: enrollment on track supports bull case, delay tightens cash crisis
Financing round: non-dilutive deal preserves thesis, heavy dilution at low price impairs it
FDA xenotransplantation guidance: clear pathway expands optionality; silence limits near-term value

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

2 programs · 8 catalysts

Stress Test